Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$17.75 USD
-0.85 (-4.55%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $17.74 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
URGN 17.75 -0.85(-4.55%)
Will URGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for URGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for URGN
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
URGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Other News for URGN
UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation
UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...
Q2 2025 Urogen Pharma Ltd Earnings Call Transcript
UroGen Pharma reports Q2 EPS ($1.05), consensus (83c)